Results 41 to 50 of about 13,254 (218)

Cilastatin Ameliorates Rhabdomyolysis-induced AKI in Mice

Journal of the American Society of Nephrology, 2021
Visual Abstract Significance Statement Rhabdomyolysis causes severe AKI and death in settings such as earthquakes and armed conflict. Specific treatment is not available and care is difficult to provide in these austere environments.
Katsuyuki Matsushita, K. Mori, Turgay Saritas, Mahaba B Eiwaz, Y. Funahashi, Megan N Nickerson, Jessica F. Hebert, A. Munhall, J. McCormick, M. Yanagita, M. Hutchens   +10 more
semanticscholar   +1 more source

Imipenem/cilastatin/relebactam dosing regimen justification using exposure-efficacy analyses in participants with hospital-acquired bacterial pneumonia or ventilator-associated bacterial pneumonia in the RESTORE-IMI 2 phase 3 study. [PDF]

Antimicrob Agents Chemother
Patel M, Nieddu G, DeRyke CA, Young K, Chen LF, Paschke A, Rizk ML, Gheyas F.   +7 more
europepmc   +2 more sources

Early Multicenter Experience With Imipenem-Cilastatin-Relebactam for Multidrug-Resistant Gram-Negative Infections

Open Forum Infectious Diseases, 2021
A multicenter case series of 21 patients were treated with imipenem-cilastatin-relebactam. There were mixed infection sources, with pulmonary infections (11/21,52%) composing the majority. The primary pathogen was Pseudomonas aeruginosa (16/21, 76%), and
N. Rebold, Taylor Morrisette, A. Lagnf, S. Alosaimy, Dana J. Holger, Katie E. Barber, J. Justo, Kayla Antosz, T. Carlson, Jeremy J. Frens, M. Biagi, W. Kufel, W. Moore, Nicholas J. Mercuro, Brian R. Raux, M. Rybak   +15 more
semanticscholar   +1 more source

Population pharmacokinetic/pharmacodynamic assessment of imipenem/cilastatin/relebactam in patients with hospital‐acquired/ventilator‐associated bacterial pneumonia

Clinical and Translational Science, 2021
In the phase III RESTORE‐IMI 2 study (ClinicalTrials.gov: NCT02493764), the combination antibacterial agent imipenem/cilastatin/relebactam (IMI/REL) demonstrated noninferiority to piperacillin/tazobactam for the end points of all‐cause mortality at day ...
Munjal Patel, F. Bellanti, Naveen M. Daryani, N. Noormohamed, D. Hilbert, K. Young, P. Kulkarni, W. Copalu, F. Gheyas, M. Rizk   +9 more
semanticscholar   +1 more source

Lipidomics Reveals Cisplatin-Induced Renal Lipid Alterations during Acute Kidney Injury and Their Attenuation by Cilastatin

International Journal of Molecular Sciences, 2021
Nephrotoxicity is a major complication of cisplatin-based chemotherapy, leading to acute kidney injury in ca. 30% of patients, with no preventive intervention or treatment available for clinical use.
E. Moreno-Gordaliza, M. Marazuela, Ó. Pastor, A. Lázaro, M. M. Gómez-Gómez   +4 more
semanticscholar   +1 more source

Alteration in Acute Kidney Injury Potential with the Combination of Vancomycin and Imipenem-Cilastatin/Relebactam or Piperacillin/Tazobactam in a Preclinical Model

Antimicrobial Agents and Chemotherapy, 2021
The risk of vancomycin (VAN)-associated acute kidney injury (AKI) may be altered with combination regimens. The specific AKI risk when VAN is combined with imipenem-cilastatin/relebactam (IMP-C/REL) or piperacillin/tazobactam (TZP) has not been clearly ...
Miao He, Ernane Souza, Aleksas Matvekas, R. Crass, M. Pai   +4 more
semanticscholar   +1 more source

In vitro study of the embolic characteristics of imipenem/cilastatin particles

CVIR Endovascular
Imipenem/cilastatin (IPM/CS) has long been administered intravenously as a carbapenem antibiotic. However, since this agent is poorly soluble in liquid, occasional reports have described its use as a short-acting, temporary embolic agent.
Hiroki Nakamura, A. Yamamoto, Takeshi Fukunaga, Hiroyuki Watanabe, Kosuke Ito, Atushi Higaki, A. Kanki, Yoshihiko Fukukura, T. Tamada   +8 more
semanticscholar   +1 more source

Pharmacokinetics and Tolerability of Intravenous Sulbactam-Durlobactam with Imipenem-Cilastatin in Hospitalized Adults with Complicated Urinary Tract Infections, Including Acute Pyelonephritis

Antimicrobial Agents and Chemotherapy, 2019
Durlobactam (DUR; ETX2514) is a novel β-lactamase inhibitor with broad-spectrum activity against Ambler class A, C, and D β-lactamases. Durlobactam restores the in vitro activity of sulbactam (SUL) against members of the Acinetobacter baumannii-A ...
Olexiy Sagan, Ruslan Yakubsevitch, K. Yanev, Р Н Фомкин, Emily Stone, Daniel J. Hines, John P. O’Donnell, Alita A. Miller, Robin Isaacs, Subasree Srinivasan   +9 more
openalex   +2 more sources

Imipenem/Cilastatin/Relebactam for Complicated Infections: A Real-World Evidence

Life
(1) Background: Infections caused by multidrug-resistant (MDR) bacteria represent one of the major global public health problems of the 21st century. Beta-lactam antibacterial agents are commonly used to treat infections due to Gram-negative pathogens ...
P. Sansone, L. Giaccari, Giusy di Flumeri, M. Pace, V. Pota, F. Coppolino, Simona Brunetti, C. Aurilio   +7 more
semanticscholar   +1 more source

Risk of Acute Kidney Injury Associated With Nephrotoxic Burden in Hospitalized Patients: A Scoping Review

Clinical Pharmacology &Therapeutics, Volume 119, Issue 4, Page 891-904, April 2026.
Limited evidence exists synthesizing the risk of acute kidney injury (AKI) associated with the concomitant administration of multiple nephrotoxic drugs, and even less examining the concept of nephrotoxic burden. The objective of this scoping review was to (1) identify definitions of nephrotoxic burden; (2) methods used to quantify (use of calculations)
Wafa Alatawi, Jessica L. Wallace, Dhakrit Rungkitwattanakul, Britney A. Stottlemyer, Tiffany L. Tran, Melanie Manis Reida, Sandra L. Kane‐Gill   +6 more
wiley   +1 more source